JP2015524422A - ワクチン組成物 - Google Patents

ワクチン組成物 Download PDF

Info

Publication number
JP2015524422A
JP2015524422A JP2015523550A JP2015523550A JP2015524422A JP 2015524422 A JP2015524422 A JP 2015524422A JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015524422 A JP2015524422 A JP 2015524422A
Authority
JP
Japan
Prior art keywords
seq
dengue
polypeptide
sequence
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524422A5 (enExample
Inventor
ジャンシェン・ヤオ
イヴ・ジレール−シャンバ
イザベル・ルガステロワ
ナタリー・マンテル
ヴェロニク・バルバン
ジャン・ラング
ブリューノ・ギィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of JP2015524422A publication Critical patent/JP2015524422A/ja
Publication of JP2015524422A5 publication Critical patent/JP2015524422A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015523550A 2012-07-24 2013-07-24 ワクチン組成物 Pending JP2015524422A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305908.1 2012-07-24
EP12305911.5 2012-07-25
EP12305911 2012-07-25
PCT/EP2013/065669 WO2014016362A1 (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Publications (2)

Publication Number Publication Date
JP2015524422A true JP2015524422A (ja) 2015-08-24
JP2015524422A5 JP2015524422A5 (enExample) 2016-09-08

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523550A Pending JP2015524422A (ja) 2012-07-24 2013-07-24 ワクチン組成物

Country Status (15)

Country Link
US (1) US20150265695A1 (enExample)
EP (1) EP2877207A1 (enExample)
JP (1) JP2015524422A (enExample)
KR (1) KR20150036593A (enExample)
CN (1) CN104812408A (enExample)
AU (1) AU2013295016A1 (enExample)
BR (1) BR112015001313A2 (enExample)
CA (1) CA2878599A1 (enExample)
GT (1) GT201500005A (enExample)
HK (1) HK1212905A1 (enExample)
MX (1) MX2015000446A (enExample)
PE (1) PE20150356A1 (enExample)
PH (1) PH12014502875A1 (enExample)
SG (1) SG11201500439RA (enExample)
WO (1) WO2014016362A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019124557A1 (ja) 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
JP2022531976A (ja) * 2019-05-15 2022-07-12 コーダ－ジェニックス・インコーポレイテッド 弱毒化黄熱ウイルス及びがんの処置のためのその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3166063A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MY187896A (en) * 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
MX383329B (es) * 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
RS65084B1 (sr) * 2015-09-29 2024-02-29 Boehringer Ingelheim Animal Health Usa Inc Vakcine čestica sličnih virusu (vlp) parvovirusa pasa (cpv) i njihova upotreba
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
IL298307A (en) 2018-09-05 2023-01-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN120271718A (zh) * 2024-01-05 2025-07-08 北京昌平实验室 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506039A (ja) * 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
JP2004532023A (ja) * 2001-04-04 2004-10-21 アメリカ合衆国 フラビウイルス感染症の予防のための核酸ワクチン
JP2007505624A (ja) * 2003-09-17 2007-03-15 デューク・ユニバーシティー コンセンサス／先祖免疫原
WO2011062625A2 (en) * 2009-11-18 2011-05-26 The Board Of Regents Of The University Of Texas System Physicochemical (pcp) based consensus sequences and uses thereof
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
CA2365411A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
US7094411B2 (en) 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
JP2005518332A (ja) 2001-05-23 2005-06-23 デンドレオン コーポレイション 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
JP2005501532A (ja) 2001-06-01 2005-01-20 アカンビス インコーポレーティッド キメラフラビウイルスベクター
AU2002330672A1 (en) 2001-07-25 2003-02-17 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
HUE037330T2 (hu) * 2002-05-03 2018-08-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN106421743A (zh) * 2009-07-29 2017-02-22 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
EP3932422A1 (en) * 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506039A (ja) * 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
JP2004532023A (ja) * 2001-04-04 2004-10-21 アメリカ合衆国 フラビウイルス感染症の予防のための核酸ワクチン
JP2007505624A (ja) * 2003-09-17 2007-03-15 デューク・ユニバーシティー コンセンサス／先祖免疫原
WO2011062625A2 (en) * 2009-11-18 2011-05-26 The Board Of Regents Of The University Of Texas System Physicochemical (pcp) based consensus sequences and uses thereof
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUMAN VACCINES, vol. 6, no. 9, JPN6017012166, 2010, pages 696 - 705, ISSN: 0003534397 *
JOURNAL OF INFECTIOUS DISEASES, vol. 209, no. 2, JPN7017004204, 2014, pages 56 - 60, ISSN: 0003899295 *
VACCINE, vol. 18, JPN6017012173, 2000, pages 44 - 47, ISSN: 0003534398 *
VACCINE, vol. 29, JPN6017012165, 2011, pages 7229 - 7241, ISSN: 0003534396 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019124557A1 (ja) 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
JP2022531976A (ja) * 2019-05-15 2022-07-12 コーダ－ジェニックス・インコーポレイテッド 弱毒化黄熱ウイルス及びがんの処置のためのその使用

Also Published As

Publication number Publication date
PE20150356A1 (es) 2015-03-20
CA2878599A1 (en) 2014-01-30
PH12014502875A1 (en) 2015-02-23
GT201500005A (es) 2015-10-13
MX2015000446A (es) 2015-03-12
SG11201500439RA (en) 2015-02-27
CN104812408A (zh) 2015-07-29
AU2013295016A1 (en) 2015-01-29
WO2014016362A1 (en) 2014-01-30
EP2877207A1 (en) 2015-06-03
HK1212905A1 (zh) 2016-06-24
US20150265695A1 (en) 2015-09-24
BR112015001313A2 (pt) 2017-08-01
KR20150036593A (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
JP6830118B2 (ja) ワクチン組成物
JP2015524422A (ja) ワクチン組成物
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
TWI852899B (zh) 疫苗組合物
RU2376374C2 (ru) Вакцина против вируса лихорадки западного нила
WO2014083194A1 (en) Methods for inducing antibodies
CA2878682C (en) Vaccine compositions for use in a method of protecting a human subject against dengue disease
HK1212906B (en) Vaccine compositions
BR112015001145B1 (pt) Composição de vacina para uso em um método de proteção de um indivíduo humano contra a doença da dengue, kit compreendendo a mesma e seu uso
HK1242193A1 (en) Vaccine compositions against dengue virus diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181023